

Review article

Ocular cicatricial pemphigoid. From a rheumatology and ophthalmology point of view[☆]



Ariana Ringer^{a,*}, German Daniel Grossi^b, Carlos Siegrist^c, Nadia Cuadranti^a, Juan Pablo Ruffino^a, María Cecilia Argento^a, María Florencia Martínez^a, Daniela Carbone^a, Serenela Chulibert^a, Marcelo Abdala^a

^a Rheumatology Service, Hospital Provincial del Centenario, Universidad Nacional de Rosario, Rosario, Argentina

^b Ophthalmology Service, Hospital Provincial del Centenario, Universidad Nacional de Rosario, Rosario, Argentina

^c Clínica de Medicina y Laboratorio Bioquímico e Inmunológico (CM/LABI Clinic of Specialized Medicine and Biochemistry), Rosario, Argentina

ARTICLE INFO

Article history:

Received 5 August 2020

Accepted 30 December 2020

Available online 24 December 2021

Keywords:

Pemphigoid, Benign mucous membrane

Ocular cicatricial pemphigoid

Benign mucosal pemphigoid

Dry eye syndromes

Conjunctivitis

Diagnostic techniques

ophthalmological

Therapeutics

Immunosuppressive agents

immunomodulation

ABSTRACT

Ocular cicatricial pemphigoid (OCP) is a chronic, immune-mediated, bullous, cicatricial disease within the spectrum of mucocutaneous membranous pemphigoids (MMP). Although the diagnosis is often ophthalmological, due to the autoimmune nature of the pathology, it requires a joint approach with rheumatologists and immunologists. The objective of this narrative review was to explore the evidence available in the literature from 2000 to 2020 with respect to clinical manifestations, diagnosis, and treatment. The clinical presentation varies widely, from mild cases with slow progression of years of progression, to severe cases with a torpid and rapidly progressive evolution to fibrosis, refractory to multiple treatments. A complete evaluation of the patient will help guide the diagnosis. The gold standard for diagnosis is conjunctival biopsy with direct immunofluorescence, although on occasions it can be reached if the symptoms are characteristic. Treatment is local and systemic according to its severity and evolution. The evidence on topical and systemic therapeutics is obtained mainly from uncontrolled observational and experimental studies. Immunomodulatory therapy has made it possible to preserve vision and, in many cases, prevent sequelae. The evolution is linked to the early diagnosis and immunosuppressive treatment, so it is essential to be aware of this disease, the diagnostic methods, as well as the immunomodulating and immunosuppressive therapies available.

© 2021 Asociación Colombiana de Reumatología. Published by Elsevier España, S.L.U. All rights reserved.

[☆] Please cite this article as: Ringer A, Grossi GD, Siegrist C, Cuadranti N, Ruffino JP, Argento MC, et al. Pemphigoides oculares cicatrizales, enfoque diagnóstico y terapéutico integral entre el oftalmólogo y el reumatólogo. Rev Colomb Reumatol. 2022;29:57-67.

* Corresponding author.

E-mail address: Aruris15151@gmail.com (A. Ringer).

Penfigoide ocular cicatrizal, enfoque diagnóstico y terapéutico integral entre el oftalmólogo y el reumatólogo

R E S U M E N

Palabras clave:

Penfigoide benigno de la membrana mucosa
 Penfigoide mucomembranoso benigno
 Penfigoide cicatrizal
 Síndromes de ojo seco
 Conjuntivitis
 Técnicas de diagnóstico oftalmológico
 Terapéutica
 Fármacos inmunosupresores
 inmunomodulación

El penfigoide ocular cicatrizal (POC) es una enfermedad crónica, inmunomediada ampollar, mucosinequante, comprendida dentro del espectro de penfigoides membranosos mucocutáneos (PMM). El diagnóstico es, con frecuencia, oftalmológico, pero debido al carácter autoinmune de la patología, requiere el abordaje en conjunto con reumatólogos e inmunólogos. El objetivo de esta revisión narrativa fue explorar la evidencia disponible en la literatura, desde el año 2000 hasta el 2020, en lo que respecta a sus manifestaciones clínicas, diagnóstico y tratamiento. La presentación clínica varía ampliamente, desde casos leves con progresión lenta de años de evolución hasta casos severos con evolución tórpida y rápidamente progresiva a la fibrosis, refractarios a múltiples tratamientos. Una evaluación completa del paciente ayudará a guiar el diagnóstico. El estándar de oro diagnóstico es la biopsia conjuntival con inmunofluorescencia directa, si bien en ocasiones puede diagnosticarse por la clínica característica. El tratamiento es local y sistémico de acuerdo con su severidad y evolución. En los últimos 20 años, la evidencia sobre los tratamientos tópicos y sistémicos corresponde en su mayoría a estudios observacionales y experimentales no controlados. Los métodos de tratamiento inmunomoduladores han permitido preservar la visión y, en muchos casos, prevenir secuelas. La evolución está ligada al diagnóstico temprano y a los tratamientos disponibles, por lo que es fundamental el conocimiento de esta patología, los métodos diagnósticos y los tratamientos inmunomoduladores e inmunosupresores.

© 2021 Asociación Colombiana de Reumatología. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Introduction

Ocular cicatricial pemphigoid (OCP) is a chronic, immune-mediated bullous disease, included within the spectrum of mucocutaneous membranous pemphigoids (MMP). In MMP any mucous membrane, such as the trachea, larynx, esophagus, vagina, anus or urethra can be affected, while when the compromise is essentially of the ocular conjunctiva receives the name of OCP, which is evidenced in 32-48% of the MMPs.¹⁻⁵

It affects approximately 1.3 to 2 people per million inhabitants, with a higher incidence in people between 50-60 years of age, although age variations between 20 and 80 years have been reported as well as a female predominance of 2-3:1. Different series estimate an annual incidence of 1 in 15,000-46,000 ophthalmological patients. The estimated prevalence in the United States was 1/20,000 to 1/60,000 in ophthalmology consultations, and in the Hispanic population the number of reported patients is limited, so a low prevalence or an underdiagnosis or underreporting of the pathology is suspected.³⁻¹³

Even though the etiopathogenesis of OCP is not exactly known, it is suggested that genetic and environmental factors could be involved, producing a type II hypersensitivity response. It is characterized by autoantibodies directed against the anchoring sites between the epithelial cells and the basement membrane, being the main site of involvement the epithelial basement membrane, unlike other bullous diseases such as pemphigus. The antigen-antibody interaction leads to the initiation of the inflammatory cascade, producing an acute and chronic inflammation with scar formation. In the

epithelial basement membrane, there is a deposition of IgA, IgG, IgM and c3 (IgG and IgA more frequently) and fragments of complement. This deposition is linear, unlike other entities that have a granular deposition. They have been described as antigens involved in the hemidesmosomal proteins, laminins, integrins and collagens.^{3,4,6-8}

In the acute phase, eosinophils and neutrophils are observed, while in the chronic phase, lymphocytes and fibroblasts are predominantly detected at the subepithelial level. Diverse cytokines, such as IL-1, IL-2, IL-4, IL-5, IL-6, IL-13, IL-17, TNF α , TNF γ and colony growth factors have been observed in abundant amounts in the conjunctiva. IL-13, TNF α and the growth factor β 1 have a profibrotic and proinflammatory effect, activating and perpetuating the survival of fibroblasts with the consequent deposition of collagen. Elevated levels of IL-8, metalloproteinases and myeloperoxidases⁹⁻¹¹ have been detected in tear samples.

The diagnosis is often ophthalmological, but due to the autoimmune nature of the pathology it requires a joint approach with rheumatologists and immunologists. The understanding of the OCP has changed significantly in the last few decades. The contribution of basic sciences has been key in the description of the processes that participate in the immune response. Immunomodulatory therapy has allowed to preserve the vision and, in many cases, to prevent the fatal consequences for it in the course of the disease. The evolution is linked to early and timely diagnosis and immunosuppressive treatment,^{3,4,6-8} and for this reason, knowledge of this pathology and the available evidence is substantial. The progression of the disease can lead to functional disability, such

as corneal blindness, with an impact on the quality of life. On the other hand, the socioeconomic costs of patients with disabilities, added to immunosuppressive treatments, reinforce the need for an early diagnosis and treatment.¹⁴⁻¹⁶

The objective of this article is to make a review of the evidence published in the last 20 years, from 2000 to 2020, regarding the clinical manifestations, diagnosis and treatments available for patients with ocular cicatricial pemphigoid in different evolutionary stages, in order to update and familiarize doctors in general with the subject.

Materials and methods

Narrative review of the literature. A literature search was conducted in PubMed, Cochrane Library, Lilacs, Epistemonikos and SciELO on the evidence available in the last 20 years, from 2000 to 2020 in relation to the clinical manifestations, the diagnosis and the treatments available in patients with ocular cicatricial pemphigoid in different evolutionary stages. Full articles, with experimental and observational study designs, reviews, case series and case reports were included. Abstracts, repeated articles and those in languages other than Spanish and English were excluded. The search strategy consisted in searching controlled terms in the Virtual Health Library, Health Sciences Descriptors (DeCS) or Medical Subject Readings, in English and in Spanish, with Boolean operators.

[Penfigoide Benigno de la Membrana Mucosa / Pemphigoid, Benign Mucous Membrane / Penfigoide Mucomembranoso Benigno / Ocular cicatricial pemphigoid / Penfigoide ocular cicatrizal / Síndromes de Ojo Seco / Dry Eye Syndromes] AND [Terapéutica / Therapeutics OR Dapsona / Dapsone OR Sulfasalazina / Sulfasalazine OR Pentoxifilina / Pentoxifylline OR Hidroxicloroquina / Hydroxychloroquine OR Metotrexato / Methotrexate OR Azatioprina / Azathioprine OR Leflunamida / Leflunomide OR Tacrolimus / Tacrolimus Ácido Micofenólico / Mycophenolic Acid OR Ciclofosfamida / Cyclophosphamide OR Rituximab / Rituximab OR Inmunoglobulinas Intravenosas / Immunoglobulins, Intravenous OR Adalimumab / Adalimumab OR Etanercept / Etanercept OR Infliximab / Infliximab OR Certolizumab Pegol / Certolizumab Pegol OR golimumab/golimumab].

[Penfigoide Benigno de la Membrana Mucosa / Pemphigoid, Benign Mucous Membrane / Penfigoide Mucomembranoso Benigno / Ocular cicatricial pemphigoid / Penfigoide ocular cicatrizal] AND Diagnóstico / Diagnosis OR Técnicas de Diagnóstico Oftalmológico / Diagnostic Techniques, Ophthalmological.

[Penfigoide Benigno de la Membrana Mucosa / Pemphigoid, Benign Mucous Membrane / Penfigoide Mucomembranoso Benigno / Ocular cicatricial pemphigoid / Penfigoide ocular cicatrizal] AND Manifestaciones Oculares / Eye Manifestations.


The search was expanded with non-controlled terms in the gray literature such as: tofacitinib, baricitinib, tocilizumab, cyclosporin A, tacrolimus and guides using Google Scholar and OpenGray. Two abstracts were included in these cases.

The evaluation of the evidence was based on *Lancet* 2002¹⁷, where it is stipulated, according to the design of the study, that the quality of evidence I is the one that comes from at least one

randomized, controlled, well-designed clinical trial; II-1 is that obtained from a non-randomized controlled clinical study; II-2 is obtained from a well-designed case-control or cohort study, preferably from more than one study center or group; II-3 is obtained from multiple series of cases with or without intervention and from important results of uncontrolled experimental studies; and III is obtained from the opinion of experts, based on clinical experience, descriptive studies or reports from expert committees.

Results

Search and selection flowchart



Clinical manifestations

The clinical presentation varies widely, from mild cases with slow progression and years of evolution to severe cases with torpid and rapidly progressive evolution to fibrosis, refractory to multiple treatments. The majority of patients have a slow evolution, with occasional exacerbations.^{3,4,6-8}

The onset can be unilateral or bilateral; and it usually involves both eyes. When it is unilateral, the contralateral eye is usually affected within 2 years. The OCP usually manifests initially as recurrent conjunctivitis, red eye or hyperemia, burning, pain, itching, lacrimation, photophobia, and foreign body sensation. It can evolve to a progressive keratopathy with neovascularization and conjunctivalization of the cornea, subsequently, appears the symblepharon, defined as a scar adherence that occurs between the conjunctiva of the eyelid and the eyeball, which can be visualized by depressing the lower eyelid and observing vertical conjunctival folds. In more advanced stages it evolves to ankyloblepharon, which is the fusion of the edges of the eyelids, generally in the area nearest to the outer canthus and with disappearance of the conjunctival sac. Dry eye of variable severity according to the stage is observed in OCP. The three layers of the lacrimal film (mucinous, aqueous and lipid) are altered. In late forms, the goblet cells of the conjunctival epithelium, which secrete mucin and help maintain the lacrimal layer, diminish or disappear. On the other hand, the scarring leads to the dysfunction of the Meibomian glands, fibrosis of their orifices and consequent

Table 1 – Classification.

<i>Foster classification</i>	
Stage 1	Presence of subepithelial fibrosis and conjunctival inflammation
Stage 2	Presence of retraction of the conjunctiva with shortening of the fornices
Stage 3	Presence of symblepharon
Stage 4	Presence of ankyblepharon
<i>Mondino and Brown classification</i>	
Stage 1	Loss of fornix depth between 0 and 25%
Stage 2	Loss of fornix depth between 25 y 50%
Stage 3	Loss of fornix depth between 50 and 75%
Stage 4	Loss of fornix depth between 75 and 100%

Source: Foster,¹ Mondino and Brown.²

alteration of the lipid layer, this being the one that most affects the evaporation and stability of the tear.^{3,4,6-8,11-13,18}

Conjunctival cicatrization can lead to entropion (inversion of the eyelid), trichiasis and distichiasis (eversion and abnormal growth of the eyelashes, secondary to the cicatrization of the margin of the eyelid) and lagophthalmos (impossibility to close completely the eyelids, with difficulty in the distribution of the tear over the ocular surface.) The ocular exposure in turn leads to corneal damage, with erosions that together with dryness, distichiasis and lagophthalmos promote the appearance of pannus, pseudopterygium and greater scarring with alteration of the vision to a variable degree and even blindness. In turn, bacterial superinfection is also frequent. In very severe cases a corneal perforation can occur. In ophthalmological practice, the most frequent initial presentation and which raises the suspicion of the diagnosis is a chronic conjunctivitis, with eye dryness, small conjunctival scars, distichiasis and narrowing or occlusion of the lacrimal points.^{3,4,6-8,10-13,18-20}

It has been suggested that even in cases in which the conjunctiva appears white and without inflammation, there may be unobservable underlying inflammatory infiltrates (*white inflammation, hidden inflammation*), which could continue to stimulate the fibrotic process.^{11,20,21}

There are various classifications: Foster's¹ is based on clinical signs of progression, while that of Mondino and Brown² is based on the evaluation of the depth of the inferior fornix. The compromise is usually asymmetric, and different stages can be observed in both eyes (Table 1).

The classification according to the severity is also important: the presence of subconjunctival scarring and fibrosis is considered *mild*; *moderate*, the shortening of the inferior cul-de-sac of the eye; *severe*, the presence of symblepharon with horizontal involvement; and *very serious*, the observation of ankyblepharon. Activity is evaluated by the presence of photophobia, ocular pain, conjunctival vascularization and hyperemia, edema and progressive cicatrization.⁷

Detailed ophthalmological description of the different stages^{1,2}

Stage 1: It includes conjunctival inflammation, secretions, epithelial sectors that stain with Rose Bengal and subepithelial fibrosis. This fibrosis is very subtle and it can be observed only with a slit lamp, it appears as very fine striae that surround the vessels, and these striations of abnormal connective tis-

sue are the ones that finally become contracted and will cause conjunctival retraction.

Stage 2: It is characterized by conjunctival retraction and shortening of the conjunctival cul-de-sac, the angle that the conjunctiva forms from the eyelid to the fornix is reduced, and the letters are used to describe the degree of shortening of the fornix: a) 0-25%, b) 25-50%, c) 50-75% and d) 75-100%.

Stage 3: Bands of connective tissue that give rise to symblepharon are added. The letters are also used to determine the percentage of horizontal compromise of the symblepharon: a) 0-25%, b) 25-50%, c) 50-75% and d) 75-100%. Trichiasis, distichiasis and decreased production of tears also appear with the progressive conjunctival retraction.

Final stage or 4: a severe dry eye syndrome, keratinization of the ocular surface and ankyblepharon appear.

Images of patients with the clinical signs of the different stages of the disease are presented in Fig. 1.

Diagnosis

A complete evaluation of the patient, with anamnesis and physical examination, will help guide the diagnosis. The gold standard is the *conjunctival biopsy*, after which direct immunofluorescence (DIF) shows a linear deposition of Ig or complement at the level of the conjunctival basement membrane. The histopathology may reveal other entities, such as for example, granulomas in sarcoidosis or granulomatosis with polyangiitis. The *biopsy* must include two samples of tissue adjacent to an inflamed site, one for the routine anatomopathological study and the other for the DIF. In patients with involvement of other mucous membranes (MMP), initial biopsies should not be taken from the ocular conjunctiva. The sample obtained is stained with hematoxylin-eosin and with alkaline Giemsa. The inflamed conjunctiva shows infiltration of neutrophils, macrophages, plasma cells, lymphocytes, eosinophils, and Langerhans cells. In advanced stages of the disease, the decrease or absence of goblet cells is notable. However, these findings are not pathognomonic of PCO and vary according to the stage of the disease and the sector in which the sample was taken. The diagnosis of certainty is established with the DIF of the biopsy. For this, linear deposits of IgG, IgM and IgA and c3 must be observed in the basement membrane. The positivity of the biopsy varies between 20 and 67% according to the series. The use of immunoperoxidase in DIF-negative biopsies from suspicious patients increased the sensitivity from 52% to 83%.^{6-10,22,23}

In some occasions, the biopsy may be inconclusive and the DIF may be negative. The Group for the Study of the Mucous Membrane Pemphigoid considers that if the ophthalmological criteria for MMP are met, but with an inconclusive biopsy, the case could be defined as MMP with negative immunofluorescence.^{23,24}

Regarding the *laboratory studies*, some antibodies present in certain cases of MMP, such as anti-laminin 5 and 6, anti-antigen 168kd, anti b4-integrin, anti-bullous pemphigo 1 and 2 and anti-collagen type VII have been detected, among others. It is necessary to have more evidence of their usefulness in different cases. On the other hand, they are not very accessible in daily practice and their costs are very high. To date, there are no sensitive or specific laboratory studies available




Fig. 1 – Ocular manifestations in OCP.

A) Conjunctival enanthema, stage 1 (Foster). B) Entropion and distichiasis. C) Subepithelial fibrosis, shortening of the inferior fornix and conjunctival symblepharon, stages 2-3 (Foster). D) More advanced symblepharon, stage 3 (Foster). E) Ankyloblepharon, stage 4 (Foster). F) Total epidermal growth on the ocular surface. G) Corneal perforation.

Figures adapted from López Gamboa et al.,⁷⁵ Espino-Barros Palau et al.,¹² Chan et al.,⁴ Feizi and Roshandel,⁷⁶ Dart³⁶ and Chirinos-Saldana et al.⁷⁷

for the diagnosis and follow-up of the therapeutic response of OCP.^{7,9,10,18,22-24}

Other *ophthalmological findings*, such as eye dryness and alterations of the corneal epithelium, can be evaluated by means of various tests. Among them, the *tear break-up time* (TBUT) is the most widely used to assess the stability of the tear film (time between a complete blink and the appearance of the first break-up of the tear film). A TBUT of less than 10 seconds is considered abnormal. Meanwhile, *Schimer's test* assesses the tear production by placing a strip of graph paper between the outer half of the lower eyelid and the bulbar conjunctiva of each eye, keeping the eyes closed for 5 minutes. The proposed abnormal values vary between ≤ 5 mm and ≤ 10 mm. Other measures corresponding to dry eye are *tear hyperosmolarity*, considered abnormal above 308 mOsm/L. *Stainings* with fluorescein and its derivative, lissamine green, which stain the damaged cells and the filaments of lacrimal mucin, can be used to assess corneal epithelial defects. Finally, there are analytical tests such as the *impression cytology* and the *detection of inflammatory mediators* such as cytokines, metalloproteinases and tumor necrosis factor in tears.^{25,26}

Among the differential diagnoses of *cicatricial conjunctivitis* (OCP corresponds to 61% of the cicatricial conjunctivitis) are those after chemical burns, ocular surgical procedures, trauma, Stevens-Johnson syndrome, epidemic keratoconjunctivitis due to adenovirus, beta-hemolytic streptococcus, trachoma, diphtheria, dermatitis herpetiformis, atopic and drug-induced keratoconjunctivitis (drugs used in glaucoma), ocular rosacea, pemphigus vulgaris, among others. There are rheumatological pathologies that can manifest as cicatricial conjunctivitis; such is the case of granulomatosis with polyangiitis, Sjögren's syndrome, scleroderma, lichen planus and sarcoidosis. It has occasionally been reported in association with other autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis and autoimmune thyroiditis, among others.²⁷⁻²⁹ OCP can also be a paraneoplastic manifestation.^{30,31} On the other hand, some topical and systemic drugs can cause the appearance of pseudopemphigoids, as a consequence of antigen exposure after tissue damage. Such drugs include topical pilocarpine, epinephrine, and echothiophate, as well as systemic practolol.^{9,18,22,32-34}

It has been reported a mean diagnostic delay of two and a half years, with a variation of up to more than 10 years.^{18,22}

Treatment

OCP is a systemic disease, and therefore requires local and systemic treatment according to its severity and evolution. The objective is aimed to control inflammation, facilitate repair and prevent scarring. Within the spectrum of mucous pemphigoids, those with ocular involvement are considered severe and high risk (like the tracheal or genital, among others), therefore, they require systemic treatment in all cases.^{7,10,18,20,35}

Topical therapy is used in addition to systemic treatment. The prescription schemes are tailored to the needs of the patient and the clinical judgment of the ophthalmologist. In the Spanish consensus for dry eye diseases, modifications in environmental conditions, diet and drugs that could alter ocular moisture are recommended, along with the use of aqueous-based or lipid-based tear substitutes. Sometimes, tear substitutes are biological as is the case of autologous serum and plasma rich in growth factors. Topical anti-inflammatory and immunomodulatory treatments such as corticosteroids, non-steroidal anti-inflammatory drugs, phenylephrine, topical formulations of cyclosporine A and tacrolimus can be added. Tear stimulants such as diquafosol sodium, rebamipide, and N-acetylcysteine are also used.^{3,15,25,26,32}

It is possible to resort to the occlusion of lacrimal puncta with devices or cauterizing them if these devices are not tolerated, so that the tears are retained and providing relief. Dystichiasis can cause punctate keratitis, ulcers, and become complicated with bacterial superinfection. Hair removal is recommended every 2 or 3 weeks. Therapeutic contact lenses can be used or, in advanced cases is necessary to resort to surgical treatments. However, these interventions can cause more inflammation and progression of the condition. Blepharoconjunctivitis is frequent due to microbial colonization of the conjunctiva and the eyelid margins, thereby stimulating further inflammation and keratitis. A prevalence of staphylococci has been found in patients with pemphigoid. It is advisable to

Table 2 – Topical treatment.

Treatment options according to the function	Types
Tear substitutes	Water-based or lipid-based artificial tears
Tear stimulation ^a	Diquafosol sodium and rebamipide N-acetyl cysteine
Biological tear substitutes	Autologous serum and plasma rich in growth factors
Topical anti-inflammatory and immunomodulatory therapy	Topical corticosteroids: hydrocortisone, prednisone, methylprednisolone, dexamethasone, fluorometholone Cyclosporin A Tacrolimus Non-steroidal antiinflammatory drugs Phenylephrine
Topical antibiotics	Tetracycline and analogues (minocycline and doxycycline)
Topical regenerative agents	Macrolides such as azithromycin

The dosage usually varies according to the need of the patient and the criterion of the ophthalmologist.

^a Oral option: pilocarpine.

carry out daily eyelid hygiene and treat Meibomian gland dysfunctions, using local and oral antibiotics when the condition requires it. If superinfection is suspected, antibiotic treatment should be incorporated.^{3,15,25,26,32} Topical treatments are detailed in [Table 2](#).

Systemic immunosuppressive treatment has been classically established, according to the severity and in a staggered manner.^{3,7,8,13,36,37} Therapeutic changes or additions every 3 months have been proposed if the inflammatory activity persists.^{36,38} Thus, in mild to moderate OCP (stages 1-2) it is suggested to start with topical treatment plus dapsone,^{11,18,37,39-41} sulfasalazine (SSZ)^{11,18,37,39-41} or methotrexate (MTX),^{11,18,31,37,39-42} and thereafter consider azathioprine (AZA)^{7,11,18,37,43} or mycophenolate mofetil (MMF)^{11,18,37,39,40,44,45} for moderate or moderate severe cases (stages 2 or 2-3). They can be used in combination (dapsone and SSZ in combination with MMF, MTX, AZA or cyclophosphamide,^{18,37} or MTX plus AZA).⁷ In severe cases (stages 3-4), MMF or cyclophosphamide,^{18,37,40,41,44,46,47} and in very severe, resistant (recalcitrant) cases or in the event of adverse effects, anti-TNFs (etanercept and infliximab)^{40,48-51}, rituximab^{39,40,52-56} or IVIG.^{7,22,39,40,57-63} Other reported treatments are pentoxifylline,⁶⁴ hydroxychloroquine,⁶⁵ baricitinib and cyclosporin A⁶⁶⁻⁶⁹ in OCP and in MMP. In addition to the stages, it is important to consider in each case the disease activity and the clinical characteristics of the patient.⁷ The systemic treatments and the available evidence in relation to the search strategy, according to study design are described in [Table 3](#).

Regarding the use of corticosteroids, it is reserved for the acute control of the disease and while the full effect of the other immunosuppressive drugs is awaited. The doses and the route of administration are based on the severity of the case.

If the activity is moderate-severe, prednisone 1 mg/kg/day or pulses of methylprednisolone 500 mg/day for 3 days, with subsequent gradual decrease in the dose should be considered. In mild or mild-moderate cases, variable doses between 5-40 mg of prednisone could be sufficient to temporarily accompany the other immunosuppressive drugs. It is suggested to use the minimum dose and for the shortest possible time to achieve control the symptoms.^{7,36,37,40}

Immunosuppressive treatment should be continued for at least one year after the stabilization of the disease, and subsequently a staggered decrease should be considered.^{7,13,18,36,37,39,40} Saw et al.³⁷ observed that 41% of the eyes assessed (92/223) showed progression of scarring, continuing with minimal or mild inflammatory activity, which could not be eliminated despite immunosuppression, or after discontinuation of the treatment. Others reported scarring even in the absence of detectable inflammatory activity.^{18,36} These findings suggest that the scarring process may continue despite the control of clinically visible inflammatory activity and that current immunosuppressive treatments may not achieve complete control of the pathology. One out of every 3 patients relapses within the years after the reduction or suspension of the immunosuppression, and therefore, close follow-up is necessary despite the remission.^{18,36,37,39,40,68}

The responses to the treatments are classified as follows: *successful*, when the disease remains quiescent, with white eye for at least 3 months from the start of immunosuppression; *partially successful*, when there is partial control of the inflammation, but residual inflammation persists; *failure*, when there is an insufficient response to the drug, continuing with inflammation, or in the event of suspension of the drug due to adverse effects.³ Other definitions in the literature correspond to: *remission*, in the absence of progressive scarring and inflammatory ocular activity for ≥ 2 months; *partial remission*, when there is clinical improvement and control of the disease for ≥ 2 months; and *long-term remission*, when upon suspension of immunosuppressive treatment for ≥ 1 year, there are no detectable clinical signs of progression according to Foster's stages.^{70,71}

Discussion

In this narrative review, the evidence on the clinical presentation is abundant, with varied manifestations. Regarding the diagnosis, there is agreement that the gold standard is the biopsy, but if it is negative or immunofluorescence is not available and the symptoms are characteristic, the diagnosis can also be suspected. The delay in the diagnosis and the insidious clinical symptoms which are potentially attributable to other more frequent pathologies at the onset of the disease, usually with recurrent conjunctivitis, red eye, ocular dryness, among others, stands out. However, the evidence in the literature hierarchizes the need for timely diagnosis and treatment to prevent ophthalmological sequelae.

In the last 20 years, the evidence for systemic treatment comes mostly from observational studies, and from some experimental. However, randomized clinical trials conducted prior to the search date that demonstrated the efficacy of the use of cyclophosphamide and prednisone in advanced stages

Table 3 – Systemic treatments.

Treatments	Dose, indication and comments
Dapsone ^{6,11,18,37,39-41}	1 mg/kg/day (maximum 200 mg/day) Mild to moderate OCP. Stages 1-2. Alone or in combination Dosage of Glucose-6-phosphate dehydrogenase (G6PD) prior to its administration Frequent adverse effects and low efficacy have been reported.
Sulfasalazine (SSZ) ^{11,18,37,39-41}	1-4 g/day, according to tolerance, with progressive increases of 500 mg/day Mild to moderate OCP. Stages 1-2. Alone or in combination
Methotrexate (MTX) ^{11,18,31,37,39-42}	Recommended doses between 10 and 25 mg/weekly, accompanied by folic acid 48 h later Mild to moderate OCP. Stages 1-2. Alone or in combination High response rates in mild to moderate OCP, with few adverse effects Recommended dose 1-3 mg/kg/day
Azathioprine (AZA) ^{6,7,11,12,18,37,43}	Mild to moderate OCP. Stages 1-2. As initial therapy, or in the event of insufficient treatment with the drugs mentioned above. Option in stage 3 Saw et al. ³⁷ observed less effectiveness than with mycophenolate and cyclophosphamide for moderate-severe cases
Mycophenolate mofetil (MMF) ^{6,11,18,37,39,40,44,45}	1 g, twice daily MMF has been reported as effective for the control of moderate or severe OCP in multiple non-controlled studies, with fewer reports of adverse effects compared with cyclophosphamide. Stages 2-3 and 3-4 Saw et al. ³⁷ reported successful treatments of severe OCP in 59%
Cyclophosphamide ^{6,18,37,40,41,46,47}	Recommended dose of 1-2 mg/kg/day PO or IV at doses of 1 g/m ² (patients without renal failure), schemes with reduced doses of 500 mg every 15 days for 3 months or 500 mg monthly are also described (suggested in older adults) Indicated in severe cases or in the event of insufficient response to previous treatments. Stages 3-4 More adverse effects reported compared with mycophenolate
Anti-TNF ^{39,40,48-51}	Stages 3-4 The experience in the literature corresponds to reports of cases of OCP and MMP insufficiently treated with other immunosuppressants.
Rituximab ^{6,22,39,40,52-54}	Scheme of 375 mg/m ² weekly for 8 consecutive weeks, then monthly for 4 months more. Other possible schemes are RTX 1,000 mg, days 1 and 15, and repeat it every 6 months or in doses lower than 500 mg in selected cases Benefits after the administration of RTX in the evolution of severe PCO, refractory to the previous therapeutic steps. Stages 3-4
Rituximab plus immunoglobulin ^{3,22,57,58}	Rituximab has been used in combination with IVIG in severe, refractory cases, after insufficient response or adverse effects to other therapeutic steps to cyclophosphamide. Stages 3-4 Rituximab plus IVIG once a month until the levels of B lymphocytes reach the normal percentage, to later space the infusions by 2 weeks
Intravenous immunoglobulin (IVIG) ^{3,6,7,39,40,59-62}	Doses of 2-3 g/kg/cycle divided in 3-5 consecutive days (according to the author). Infusions are usually administered monthly, although there are reports of severe cases with infusions every 15 days. According to the literature, the duration is variable, between 3-6 cycles at least, reaching prolonged therapies of more than 3 years. Another reported scheme consists in a cycle of 2 g/kg in 2 days, followed by 3 monthly cycles of 1 g/kg infused in the same way. It is suggested to consider its use in patients with adverse effects, contraindications or who are resistant to the previous drugs. Stages 3-4 The therapy could be reduced or spaced when there is evidence of total control of the disease control for at least 3 weeks
Pentoxifylline ⁶⁴	It has been proposed that this phosphodiesterase inhibitor with an inhibitory effect on TNF would be an effective, inexpensive treatment with few adverse effects as an adjuvant therapy in OCP

of the disease stand out,^{1,72,73} in addition to a Cochrane review on interventions in mucocutaneous pemphigoid and epidermolysis bullosa.⁷⁴ Meta-analyses were not found according to the search strategy, only one randomized clinical study for pentoxifylline was found. According to the study designs, the literature presented corresponds mostly to quality II-III. On the other hand, a greater number of studies are observed in

relation to rituximab and immunoglobulin compared to others used in previous stages.

Currently, treatments are based on the staggered strategy, but the progression with irreversible scarring and the presence of white inflammation question whether this approach is correct in all cases, or if stronger immunosuppression should be started early in certain patients to prevent the

progression to fibrosis. There is not enough evidence yet to predict which patients will develop an aggressive course of the disease and whether they would benefit from a more intensive treatment since the beginning, mainly in those whose only manifestation is PCO without extraocular involvement. On some occasions, the recommendations are extrapolated from the evidence in the treatment of MMP, other ocular pathologies such as uveitis, or other systemic autoimmune diseases, and therefore, it is necessary to expand the pharmacokinetic and pharmacodynamic knowledge at the ophthalmological level. Likewise, it is probable to find in the literature cases with predominantly favorable outcomes and, therefore, an underreporting of those with negative outcomes. There is a wide variety of treatments whose indications vary according to ophthalmological findings, however, there is still not enough evidence regarding the best recommendation in each case.

Due to the fact that the onset of the condition is usually nonspecific, patients tend to wander through different institutions and professionals, frequently consulting wards only in the event of increases in symptoms. The generally limited time of these consultations, as well as the impossibility of being followed-up by the same professional, lead to poor monitoring of the clinical picture. In turn, the difficulty for the performance of the conjunctival biopsy (high costs, lack of coverage by some health systems, need for pathologists specialized in the subject, etc.) causes a delay in the diagnosis and treatment. In severe cases, diagnosed and treated late, the progression of the disease can lead to sequelae and loss of vision, so the great medical challenge is early diagnosis and its corresponding treatment.

Conclusion

OCP is an infrequent pathology compared to other autoimmune diseases, of variable severity, mostly mild to moderate cases. The clinical presentation, often non-specific and the difficulties in the performance of the conjunctival biopsy have as a consequence a delay in the diagnosis and immunosuppression, which results in the progression of the disease with fibrosis. The available evidence on immunosuppressive treatments, mainly in severe cases or refractory to initial therapies, is limited, with mostly uncontrolled studies, a reduced number of patients and short-term follow-ups.

The determination of risk factors for the progression to severe cicatricial disease and of serological markers or in conjunctival biopsies constitutes a challenge for the future, in order to predict which patients will develop a disease of rapid and aggressive progression and which will have a slow evolution and very rarely develop a mucosynequing disease.

The life expectancy of human beings has increased in the last decades, which makes them coexist with chronic diseases. A high index of suspicion and knowledge on the subject is necessary to avoid definitive ophthalmological sequelae and improve the quality of life of the patients. The interdisciplinary approach between ophthalmologists, rheumatologists and immunologists stands out. The findings of the present narrative review explore the available evidence on the clinical, diagnostic and therapeutic characteristics, most of them

being applicable in daily practice. The validity of the studies should be interpreted based on the quality and design of each one of them. Finally, it is essential to continue the study of this entity, in order to improve the quality of the available evidence and thus optimize the diagnostic and therapeutic approaches.

Conflict of interest

None.

Funding

None.

REFERENCES

1. Foster C. Cicatricial pemphigoid. *Trans Am Ophthalmol Soc.* 1986;84:527-663.
2. Mondino BJ, Brown SI. Ocular cicatricial pemphigoid. *Ophthalmology.* 1981;88:95-100, [http://dx.doi.org/10.1016/s0161-6420\(81\)35069-6](http://dx.doi.org/10.1016/s0161-6420(81)35069-6).
3. Wang K, Seitzman G, Gonzales JA. Ocular cicatricial pemphigoid. *Curr Opin Ophthalmol.* 2018;29:543-51, <http://dx.doi.org/10.1097/ICU.0000000000000517>.
4. Chan L, Ahmed AR, Anhalt GJ, Bernauer W, Cooper KD, Elder MJ, et al. The First International Consensus on Mucous Membrane Pemphigoid. Definition, diagnostic criteria, pathogenic factors, medical treatment and prognostic indicators. *Arch Dermatol.* 2002;138:370-9, <http://dx.doi.org/10.1001/archderm.138.3.370>.
5. Srikumaran D, Akpek EK. Mucous membrane pemphigoid: recent advances. *Curr Opin Ophthalmol.* 2012;23:523-7, <http://dx.doi.org/10.1097/ICU.0b013e328358bafd>.
6. Fremont F, Pelissier-Suarez C, Fournié P, Porterie M, Thevenin A, Astudillo L, et al. Clinical characteristics and outcomes of ocular cicatricial pemphigoid: a cohort study and literature review. *Cornea.* 2019;38:1406-11, <http://dx.doi.org/10.1097/ICO.0000000000002080>.
7. Juri MC, Fernández Romero D, Devoto M, Gerogiet D, Zarate J, Malbran A. Tratamiento sistémico del penfigoide cicatrizal ocular. *Medicina (B Aires).* 2012;72:103-8.
8. Murrell DF, Marinovic B, Caux F, Prost C, Ahmed R, Wozniak K, et al. Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts. *J Am Acad Dermatol.* 2015;72:168-74, <http://dx.doi.org/10.1016/j.jaad.2014.08.024>.
9. Bose T. Role of immune cells in the ocular manifestations of pemphigoid diseases. *Ther Adv Ophthalmol.* 2019;11:1-9, <http://dx.doi.org/10.1177/2515841419868128>.
10. Schmidt E, Zillikens D. Pemphigoid diseases. *Lancet.* 2013;381:320-32, [http://dx.doi.org/10.1016/S0140-6736\(12\)61140-4](http://dx.doi.org/10.1016/S0140-6736(12)61140-4).
11. Taurone S, Spoletini M, Ralli M, Gobbi P, Artico M, Imre L, et al. Ocular mucous membrane pemphigoid: a review. *Immunol Res.* 2019;4-6, <http://dx.doi.org/10.1007/s12026-019-09087-7>.
12. Espino-Barros Palau A, González-González LA, Rodríguez-García A. Presentación clínica y manejo del penfigoide cicatrizal ocular en México. *Rev Mex Oftalmol.* 2010;84:10-8.
13. Chiganer EH, Albera P. Penfigoide ocular cicatricial: hallazgos de biopsia conjuntival y su relación con la inflamación y cicatrización ocular. *Rev Mex Oftalmol.* 2017;91:134-41.
14. Didona D, Maglie R, Eming R, Hertl M. Pemphigus: Current and future therapeutic strategies. *Front Immunol.*

- 2019;10:1418, <http://dx.doi.org/10.3389/fimmu.2019.01418>.
15. Rauz S, Koay S-Y, Foot B, Kaye SB, Figueiredo F, Burdon MA, et al. The Royal College of Ophthalmologists guidelines on serum eye drops for the treatment of severe ocular surface disease: full report. *Eye (Lond)*. 2017, <http://dx.doi.org/10.1038/eye.2017.209>.
 16. Williams GP, Radford C, Nightingale P, Dart JK, Rauz S. Evaluation of early and late presentation of patients with ocular mucous membrane pemphigoid to two major tertiary referral hospitals in the United Kingdom. *Eye (Lond)*. 2011;25:1207-18, <http://dx.doi.org/10.1038/eye.2011.175>.
 17. Grimes DA, Schulz KF. An overview of clinical research: The lay of the land. *Lancet*. 2002;359:57-61, [http://dx.doi.org/10.1016/S0140-6736\(02\)07283-5](http://dx.doi.org/10.1016/S0140-6736(02)07283-5).
 18. Georgoudis P, Sabatino F, Szentmary N, Palioura S, Fodor E, Hamada S, et al. Ocular mucous membrane pemphigoid: current state of pathophysiology, diagnostics and treatment. *Ophthalmol Ther*. 2019;8:5-17, <http://dx.doi.org/10.1007/s40123-019-0164-z>.
 19. Malbran A, Devoto MH. Penfigoide cicatrizal ocular. *Medicina (B Aires)*. 2006;66:154.
 20. Buonavoglia A, Leone P, Dammacco R, Di Lernia G, Petruzzi M, Bonamonte D, et al. Pemphigus and mucous membrane pemphigoid: An update from diagnosis to therapy. *Autoimmunity Rev*. 2019;18:349-58, <http://dx.doi.org/10.1016/j.autrev.2019.02.005>.
 21. Neumann R, Tauber J, Foster CS. Remission and recurrence after withdrawal of therapy for ocular cicatricial pemphigoid. *Ophthalmology*. 1991;98:858-62, [http://dx.doi.org/10.1016/s0161-6420\(91\)32209-7](http://dx.doi.org/10.1016/s0161-6420(91)32209-7).
 22. Malbran A, Juri MC, Brunzini R, Devoto M, Georgiotti D, Larrauri B, et al. Conjuntivitis cicatrizal recalcitrante. Tratamiento de nueve pacientes con rituximab. *Medicina (B Aires)*. 2019;79:299-302.
 23. Dart J, Setterfield J, Groves RW, Mee JB, Diercks GFH, Pas HH, et al. Autoantibody detection for diagnosis in direct immunofluorescence-negative mucous membrane pemphigoid: ocular and other sites compared. *Ophthalmology*. 2021;128:372-82, <http://dx.doi.org/10.1016/j.ophtha.2020.07.052>.
 24. Ong HS, Setterfield JF, Minassian DC, Dart JK, Booth D, Reid E, et al. Mucous membrane pemphigoid with ocular involvement: the clinical phenotype and its relationship to direct immunofluorescence findings. *Ophthalmology*. 2018;125:496-504, <http://dx.doi.org/10.1016/j.ophtha.2017.10.004>.
 25. Instituto Mexicano del Seguro Social. Guía de práctica clínica. Abordaje diagnóstico y terapéutico del paciente con síndrome de ojo seco. Catálogo maestro de guías de práctica clínica [Internet]. 2010 [accessed 1 ago 2020]. Available from: www.cenetec.salud.gob.mx.
 26. Orobía AJM. Guías Españolas para el tratamiento de la enfermedad de ojo seco. Documento de Consenso. 2017 [accessed 1 ago 2020]. Available from http://www.lasuperficieocular.com/resources/documents/guias_ojo_seco.SESOC_THEA.pdf.
 27. Tarabishy AB, Schulte M, Papalioidis GN, Hoffman GS. Wegener's granulomatosis: Clinical manifestations, differential diagnosis, and management of ocular and systemic disease. *Surv Ophthalmol*. 2010;55:429-44, <http://dx.doi.org/10.1016/j.survophthal.2009.12.003>.
 28. Thorne JE, Jabs DA, Nikolskaia O, Anhalt G, Nousari HC. Case report discoid lupus erythematosus and cicatrizing conjunctivitis: clinicopathologic study of two cases. *Ocul Immunol Inflamm*. 2002;13707:287-92, <http://dx.doi.org/10.1076/ocii.10.4.287.15595>.
 29. O'Donnel JJ Jr, Karakus S, Doroslovacki P, Akpek EK. Sarcoidosis presenting with cicatrizing conjunctivitis. *Optom Vis Sci*. 2015;92:173-5, <http://dx.doi.org/10.1097/OPX.0000000000000636>.
 30. Wittenberg M, Worm M. Severe refractory paraneoplastic mucous membrane pemphigoid successfully treated with rituximab. *Front Med (Lausanne)*. 2019;6:6-11, <http://dx.doi.org/10.3389/fmed.2019.00008>.
 31. McCluskey P, Chang JH, Singh R, Wakefield D. Methotrexate therapy for ocular cicatricial pemphigoid. *Ophthalmology*. 2004;111:796-801, <http://dx.doi.org/10.1016/j.ophtha.2003.07.010>.
 32. Kirzhner M, Jakobiec FA. Ocular cicatricial pemphigoid: A review of clinical features, immunopathology, differential diagnosis, and current management. *Semin Ophthalmol*. 2011;26:270-7, <http://dx.doi.org/10.3109/08820538.2011.588660>.
 33. Chan LS. Ocular and oral mucous membrane pemphigoid (cicatricial pemphigoid). *Clin Dermatol*. 2012;30:34-7, <http://dx.doi.org/10.1016/j.clindermatol.2011.03.007>.
 34. Machín YF. Aspectos epidemiológicos y opciones de tratamiento para las complicaciones oftalmológicas de las enfermedades mucosinequiantes. *Rev Habanera Ciencias Médicas*. 2016;15:431-42.
 35. Kourosh AS, Yancey KB. Therapeutic approaches to patients with mucous membrane pemphigoid. *Dermatol Clin*. 2011;29:637-41, <http://dx.doi.org/10.1016/j.det.2011.06.022>.
 36. Dart JK. The 2016 Bowman lecture conjunctival cures: scarring conjunctivitis 30 years on. *Eye (Lond)*. 2017;31:301-32, <http://dx.doi.org/10.1038/eye.2016.284>.
 37. Saw VPJ, Dart JKG, Rauz S, Ramsay A, Bunce C, Xing W, et al. Immunosuppressive therapy for ocular mucous membrane pemphigoid. *Ophthalmology*. 2008;115:253-61, <http://dx.doi.org/10.1016/j.ophtha.2007.04.027>.
 38. Saadoun D, Bodaghi B, Bienvenu B, Sene D, Trad S, et al. Autoimmunity reviews biotherapies in inflammatory ocular disorders: interferons, immunoglobulins, monoclonal antibodies. *Autoimmun Rev*. 2013;12:774-83, <http://dx.doi.org/10.1016/j.autrev.2013.02.002>.
 39. Queisi MM, Zein M, Lamba N, Meese H, Foster CS. Update on ocular cicatricial pemphigoid and emerging treatments. *Surv Ophthalmol*. 2016;61:314-7, <http://dx.doi.org/10.1016/j.survophthal.2015.12.007>.
 40. Sobolewska, Deuter C, Zierhut M. Current medical treatment of ocular mucous membrane pemphigoid. *Ocul Surf*. 2013;11:260-6, <http://dx.doi.org/10.1016/j.jtos.2013.02.003>.
 41. Brunner M, Lacoste KJ, Bernauer W. Control of ocular disease in mucous membrane pemphigoid. *Klin Monbl Augenheilkd*. 2014;231:331-4, <http://dx.doi.org/10.1055/s-0034-1368290>.
 42. Shi Y, Xie C, He Y, Liu H, Zhu B, Zhu J. Efficacy and adverse reactions of methotrexate in the treatment of ocular cicatricial pemphigoid. *Medicine (Baltimore)*. 2018;97:38, <http://dx.doi.org/10.1097/MD.00000000000012338>.
 43. Pasadhika S, Kempen JH, Newcomb CW, Liesegang TL, Pujari SS, Rosenbaum JT, et al. Azathioprine for ocular inflammatory diseases. *Am J Ophthalmol*. 2009;148:500-9, <http://dx.doi.org/10.1016/j.ajo.2009.05.008>.
 44. Daniel E, Thorne JE, Newcomb CW, Pujari SS, Kaçmaz RO, Levy-Clarke GA, et al. Mycophenolate mofetil for ocular inflammation. *Am J Ophthalmol*. 2010;149:423-32, <http://dx.doi.org/10.1016/j.ajo.2009.09.026>.
 45. Doycheva D, Deuter C, Blumenstock G, Stuebiger N, Zierhut M. Long-term results of therapy with mycophenolate mofetil in ocular mucous membrane pemphigoid. *Ocul Immunol Inflamm*. 2011;19:431-8, <http://dx.doi.org/10.3109/09273948.2011.624288>.
 46. Thorne JE, Woreta FA, Jabs DA, Anhalt GJ. Treatment of ocular mucous membrane pemphigoid with immunosuppressive

- drug therapy. *Ophthalmology*. 2008;115:2146-52, <http://dx.doi.org/10.1016/j.ophtha.2008.08.002>.
47. Durrani K, Papaliodis GN, Foster CS. Pulse IV cyclophosphamide in ocular inflammatory disease: Efficacy and short-term safety. *Ophthalmology*. 2004;111:960-5, <http://dx.doi.org/10.1016/j.ophtha.2003.08.034>.
 48. Prey S, Robert PY, Drouet M, Sparsa A, Roux C, Bonnetblanc JM, et al. Treatment of ocular cicatricial pemphigoid with the tumour necrosis factor alpha antagonist etanercept. *Acta Derm Venereol*. 2007;87:74-5, <http://dx.doi.org/10.2340/00015555-0132>.
 49. Sacher C, König C, Scharffetter-Kochanek K, Krieg T, Hunzelmann N, Rubbert A. Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor α antagonist etanercept. *J Am Acad Dermatol*. 2002;46:113-5, <http://dx.doi.org/10.1067/mjd.2001.119100>.
 50. Hefferman MP, Bentley DD. Successful treatment of mucous membrane pemphigoid with infliximab. *Arch Dermatol*. 2006;142:1268-70, <http://dx.doi.org/10.1001/archderm.142.10.1268>.
 51. Canizares MJ, Smith DI, Conners MS, Maverick KJ, Hefferman MP. Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients. *Arch Dermatol*. 2006;142:1457-61, <http://dx.doi.org/10.1001/archderm.142.11.1457>.
 52. Le Roux-Villet C, Prost-Squarcioni C, Alexandre M, Caux F, Pascal F, Doan S, et al. Rituximab for patients with refractory mucous membrane pemphigoid. *Arch Dermatol*. 2011;147:843-9, <http://dx.doi.org/10.1001/archdermatol.2011.54>.
 53. RübSam A, Stefaniak R, Worm M, Pleyer U. Rituximab preserves vision in ocular mucous membrane pemphigoid. *Expert Opin Biol Ther*. 2015;15:927-33, <http://dx.doi.org/10.1517/14712598.2015.1046833>.
 54. Lamberts A, Euverman HI, Terra JB, Jonkman MF, Horváth B. Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases. *Front Immunol*. 2018;9:1-9, <http://dx.doi.org/10.3389/fimmu.2018.00248>.
 55. Ross AH, Jaycock P, Cook SD, Dick AD, Tole DM. The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement. *Br J Ophthalmol*. 2009;93:421-3, <http://dx.doi.org/10.1136/bjo.2007.129510>.
 56. Tony HP, Burmester G, Schulze-Koops H, Grunke M, Henes J, Kötter I, et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: Experience from a national registry (GRAID). *Arthritis Res Ther*. 2011;13:R75, <http://dx.doi.org/10.1186/ar3337>.
 57. Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid. A preliminary report. *Ophthalmology*. 2010;117:861-9, <http://dx.doi.org/10.1016/j.ophtha.2009.09.049>.
 58. You C, Lamba N, Lasave AF, Ma L, Diaz MH, Foster CS, et al. Rituximab in the treatment of ocular cicatricial pemphigoid: a retrospective cohort study. *Graefes Arch Clin Exp Ophthalmol*. 2017;255:1221-8, <http://dx.doi.org/10.1007/s00417-017-3603-3>.
 59. Sami N, Letko E, Androudi S, Daoud Y, Foster CS, Ahmed AR. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: A long-term follow-up. *Ophthalmology*. 2004;111:1380-2, <http://dx.doi.org/10.1016/j.ophtha.2003.11.012>.
 60. Letko E, Miserocchi E, Daoud YJ, Christen W, Foster CS, Ahmed AR. A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. *Clin Immunol*. 2004;11:303-10, <http://dx.doi.org/10.1016/j.clim.2003.11.002>.
 61. Ma L, You C, Hernandez M, Maleki A, Lasave A, Schmidt A, et al. Management of ocular cicatricial pemphigoid with intravenous immunoglobulin monotherapy management of ocular cicatricial pemphigoid with intravenous immunoglobulin monotherapy. *Ocul Immunol Inflamm*. 2019;27:636-42, <http://dx.doi.org/10.1080/09273948.2018.1433302>.
 62. Leuci S, Amato M, Calabria E, Piscopo R, Tranfa F, Spagnuolo G, et al. Long-term follow-up after intravenous immunoglobulin therapy in patients with severe ocular mucous membrane pemphigoid unresponsive to conventional therapy. 2018;2018:8372146, <http://dx.doi.org/10.1155/2018/8372146>.
 63. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. *Arch Dermatol*. 2003;139:1051-9, <http://dx.doi.org/10.1001/archderm.139.8.1051>.
 64. El Darouti MA, Fakhry Khattab MA, Hegazy RA, Hafez DA, Gawdat HI. Pentoxifylline (anti-tumor necrosis factor drug): Effective adjuvant therapy in the control of ocular cicatricial pemphigoid. *Eur J Ophthalmol*. 2011;21:529-37, <http://dx.doi.org/10.5301/EJO.2011.6294>.
 65. Goldich Y, Ziai S, Artornsombudh P, Avni-Zauberman N, Elbaz U, Rootman DS, et al. Characteristics of patients with ocular cicatricial pemphigoid referred to major tertiary hospital. *Can J Ophthalmol*. 2015;50:137-42, <http://dx.doi.org/10.1016/j.jcjo.2014.11.012>.
 66. Alonso A, Bignone ML, Brunzini M, Brunzini R. Ocular autoimmune pemphigoid and cyclosporin A. *Allergol Immunopathol (Madr)*. 2006;34:113-5, <http://dx.doi.org/10.1157/13088180>.
 67. Kaçmaz RO, Kempen JH, Newcomb C, Daniel E, Gangaputra S, Nussenblatt RB, et al. Cyclosporine for ocular inflammatory diseases. *Ophthalmology*. 2010;117:576-84, <http://dx.doi.org/10.1016/j.ophtha.2009.08.010>.
 68. Miserocchi E, Baltatzis S, Roque MR, Ahmed AR, Foster CS. The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid. *Ophthalmol*. 2002;109:111-8, [http://dx.doi.org/10.1016/s0161-6420\(01\)00863-6](http://dx.doi.org/10.1016/s0161-6420(01)00863-6).
 69. Sarny S, Hucke M, El-Shabrawi Y. Treatment of mucous membrane pemphigoid with janus kinase inhibitor baricitinib. *JAMA Ophthalmol*. 2018;136:1420-2, <http://dx.doi.org/10.1001/jamaophthalmol.2018.3789>.
 70. You C, Anesi SD, Foster CS. Pemphigoid off immunomodulatory therapy. *Eur J Ophthalmol*. 2018;28:157-62, <http://dx.doi.org/10.5301/ejo.5001050>.
 71. Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. *Ophthalmology*. 2014;121:785-96, <http://dx.doi.org/10.1016/j.ophtha.2013.09.048>.
 72. Elder MJ, Lightman S, Dart JK. Role of cyclophosphamide and high dose steroid in ocular cicatricial pemphigoid. *Br J Ophthalmol*. 1995;79:264-6, <http://dx.doi.org/10.1136/bjo.79.3.264>.
 73. Foster CS, Wilson LA, Ekins MB. Immunosuppressive therapy for progressive ocular cicatricial pemphigoid. *Ophthalmology*. 1982;89:340-53, [http://dx.doi.org/10.1016/s0161-6420\(82\)34791-0](http://dx.doi.org/10.1016/s0161-6420(82)34791-0).
 74. Kirtschig G, Murrell D, Wojnarowska F, Khumalo N. Interventions for mucousmembrane pemphigoid and epidermolysis bullosa acquisita. *Cochrane Database Syst Rev*. 2003;1:CD004056, <http://dx.doi.org/10.1002/14651858.CD004056>.

-
75. López Gamboa VR, Castaño MB, Videla I, Rossello VE, Van Caester R, Sambuelli G, et al. Penfigoide cicatrizal ocular. *Dermatol Argent.* 2018;24:128-32.
76. Feizi S, Roshandel D. Ocular manifestations and management of autoimmune bullous diseases. *J Ophthalmic Vis Res.* 2019;14:195-210, <http://dx.doi.org/10.4103/jovr.jovr.86.18>.
77. Chirinos-Saldaña P, Zúñiga-González I, Hernández-Camarena JC, Navas A, Ramírez-Luquin T, Robles-Contreras A, et al. Cicatricial changes in ocular pemphigus. *Eye (Lond).* 2014;28:459-65, <http://dx.doi.org/10.1038/eye.2014.3>.